NCT07448480Active, not recruiting
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas: Large Single-Center Observational Cohort Study (GLIOTARG)
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas. The study includes patients with molecularly confirmed diagnoses according to the World Health Organization (WHO) 2021 classification of Central Nervous System (CNS) tumors: glioblastomas (IDH-wildtype, WHO grade 4), astrocytomas (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytomas (WHO grade 2-3).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1000 (actual)
- First submitted
- 23 Feb 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Blokhin's Russian Cancer Research Center
- Diseases
- Glioblastoma
- NCT number
- NCT07448480
What you commit to
- Study type: Observational
- Participants enrolled: 1000
- From 1 Feb 2026 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior participation in clinical trials with unblinded investigational agents where data cannot be extracted (except where data are available and verifiable);
Other illness
- Lack of documented disease recurrence or progression, or insufficient treatment-related data in medical records to assess at least one of the study outcome measures;
- Synchronous primary malignant neoplasms.
Age
- Age \< 18 years at initial diagnosis;
Other
- Absence of molecular-genetic confirmation of the tumor (according to WHO 2021 classification);
Who the study is looking for
- Age ≥ 18 years at the time of initial brain tumor diagnosis;
- Histologically confirmed diagnosis of malignant glioma, including:
- Glioblastoma, IDH-wildtype (WHO grade 4)
- Astrocytoma, IDH-mutant (WHO grade 3-4)
- Pleomorphic xanthoastrocytoma (WHO grade 2-3)
- Molecularly confirmed diagnosis according to WHO 2021 classification (with available data on IDH1/2, BRAF, 1p/19q, and MGMT status where applicable);
- Documented disease recurrence or progression with available treatment-related data in medical records to assess at least one of the study outcome measures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Blokhin's Russian Cancer Research Center Coordinator of this site? Confirm its status | Moscow | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.